Hiro has extraordinary R&D experiences over 20 years. He leads multiple angle-organization management of both new investments including LP position and portfolio companies in Board, SAB, KOL meetings. His expertise has been delegated to any due diligence with innovative R&D activities. He has served as Head of Alliance & Management in Drug discovery research at Astellas including research collaboration and post-merger integration of Biotech and Venture. Hiro has also conducted drug discovery in Oncology in Astellas. Before that, Hiro led many new programs as head of pharmacology in Oncology Drug Discovery, Takeda Pharmaceutical Company, and Drug Discovery department in Millennium: Takeda Oncology Company. In this capacity of an officer with high responsibility, he was responsible for drug discovery from early to late-stage including innovative technologies at Japan facility as well as global drug discovery initiatives. Hiro served a number of academic lectures with academic appointments. Prior to his tenure at Takeda, he was dedicated to conducting basic research, drug discovery and translational research in St Jude Children’s Research Hospital (Dr Tom Curran, FRS, currently Executive Director and Chief Scientific Officer of the Children’s Research Institute, Children’s Mercy), in collaboration with Genentech (Dr Fred de Savage, Vice president) and Curis (Dr Lee Rubin, CSO, currently Professor at Harvard University).
Hiro received a Ph.D. with distinction in Epigenetics, Cellular Molecular Biology/Veterinary Medical Sciences from the University of Tokyo.
Currently, Hiro is appointed as a lecturer of World-leading Innovative Graduate Study Program for Life Science and Technology at the University of Tokyo.